# Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

> clinical trial · VERIFIED · 2026-06-11

Status: RECRUITING · Sponsor: Beijing Biotech · Condition: Non-Small Cell Lung Cancer

- Company: Beijing Biotech
- Sector: cell therapy
- Primary source: https://clinicaltrials.gov/study/NCT07641023

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.